ERBB2 and breast cancer: Breast cancer is stratified into distinct molecular subtypes, including Luminal A, Luminal B, HER2-positive, and triple-negative breast cancer (TNBC), each exhibiting divergent responses to therapeutic interventions, thereby underscoring the imperative for tailored treatment modalities such as chemotherapy, hormonal therapies, targeted therapies, and immunotherapies (Figure 1).